Boosting cellular sits at the center of this dementia and brain health question.

Yes, emerging evidence suggests that boosting cellular energy can help slow multiple aging-related brain disorders, and recent breakthroughs have moved this from theoretical to practically testable. Researchers have discovered that mitochondrial dysfunction—the brain’s inability to generate sufficient ATP energy—is a common hallmark of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. When brain cells lose their power source, neurons deteriorate and cognitive function declines. However, new interventions that restore cellular energy metabolism, particularly through NAD+ supplementation and mitochondrial biogenesis strategies, have shown remarkable results in early research. A 2025 study found that NAD+ supplements could correct RNA splicing errors caused by toxic tau protein and actually restore memory performance in animal models of Alzheimer’s disease.

This article explores the science of brain aging at the cellular level, explains why energy metabolism matters for neurodegenerative diseases, and examines the emerging therapies that could change how we prevent and treat these conditions. As we age, our brain’s energy production naturally declines. The mitochondria—cellular power plants—become less efficient, producing less ATP and accumulating damage over time. This energy deficit accelerates neurodegeneration, but it’s not inevitable. Several promising approaches aim to reverse or slow this decline by directly addressing the energy crisis in aging brains.

How Does Mitochondrial Dysfunction Drive Multiple Brain Diseases?
NAD+ Decline and the Energy Restoration Pathway
Glucose Metabolism Collapse in Alzheimer’s Disease
Therapeutic Strategies That Target the Energy Crisis
What Energy Restoration Cannot Yet Fix
The OTULIN Breakthrough and Immune-Driven Neurodegeneration
What’s Next—Clinical Translation and Real-World Applications
Conclusion

How Does Mitochondrial Dysfunction Drive Multiple Brain Diseases?

The brain consumes roughly 20% of the body’s energy despite representing only 2% of body weight. This extreme energy demand makes neurons particularly vulnerable when mitochondria fail. Mitochondrial dysfunction has been confirmed as a disease hallmark in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease—meaning it’s not a side effect but a core mechanism driving these conditions. As aging progresses, mitochondrial quality control systems deteriorate, reducing ATP production and allowing damaged mitochondria to accumulate in brain cells. This energy shortage cascades into problems: neurons can’t maintain proper connections, toxic proteins accumulate because the cell lacks energy to clear them, and inflammation increases as stressed mitochondria trigger immune responses. Different diseases strike the brain’s energy system in different ways.

In Parkinson’s disease, toxins like MPTP (a chemical contaminant) selectively attack Complex I of the electron transport chain, the first pump in the mitochondrial chain that generates ATP. This explains why people with Parkinson’s experience dopamine neuron death and motor dysfunction—their dopamine-producing cells are particularly energy-hungry and collapse when the power fails. Alzheimer’s disease shows a different pattern: patients exhibit significant reduction in glucose metabolic capacity compared to healthy aging brains. Toxic beta-amyloid and tau proteins also increase IDO1 enzyme activity, which hijacks astrocytes (the brain cells that normally supply energy to neurons) and prevents them from producing and delivering that energy to the neurons that desperately need it. However, the energy problem in neurodegenerative disease is not irreversible. Because all three major diseases—Alzheimer’s, Parkinson’s, and Huntington’s—share this common mitochondrial vulnerability, therapies targeting cellular energy could potentially benefit patients across multiple diagnoses. This is why researchers have become increasingly focused on restoring the brain’s power supply rather than attacking individual toxic proteins.

How Does Mitochondrial Dysfunction Drive Multiple Brain Diseases?

NAD+ Decline and the Energy Restoration Pathway

NAD (nicotinamide adenine dinucleotide) is a critical molecule that acts as a “currency” for cellular energy. It shuttles electrons through the electron transport chain in mitochondria and participates in numerous cellular repair processes. Unfortunately, NAD levels decline with advancing age—a pattern that mirrors neurodegenerative disease risk. Aging is the strongest known risk factor for Alzheimer’s and Parkinson’s, and that connection appears to run directly through declining NAD availability. When NAD levels fall, mitochondria function less efficiently, and cells can’t repair damage as quickly, creating a downward spiral of energy depletion. A major breakthrough in 2025 showed that this decline is not irreversible. When researchers gave NAD+ supplements to mice carrying tau mutations (similar to human Alzheimer’s disease), something striking happened: the NAD+ corrected RNA splicing errors caused by the toxic tau protein, restored brain function, and enhanced memory performance.

This wasn’t a mild improvement—memory was actually restored. The mechanism appears to be that NAD+ strengthens the cell’s ability to read its genetic code correctly and maintain proper protein production, essentially bypassing some of the damage tau causes. These findings have moved NAD+ supplementation from “interesting theory” to “actionable therapeutic candidate.” However, taking NAD+ supplements isn’t as simple as taking a vitamin. The body doesn’t directly absorb NAD itself—it’s broken down during digestion. Instead, researchers use precursors like nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) that the body can convert back into NAD. The challenge is getting these molecules into the brain effectively, which is why most promising research combines NAD precursors with other therapies. For example, combining NMN plus PARP1 inhibitors (compounds that slow NAD depletion) has shown better results than either alone, improving mitochondrial quality, balancing energy metabolism, and reducing brain inflammation in laboratory studies. This combination approach may be necessary to achieve clinical benefit.

Glucose Metabolism Collapse in Alzheimer’s Disease

Alzheimer’s disease shows a particular vulnerability in glucose metabolism—the primary fuel for the brain. The healthy brain efficiently converts glucose into ATP, but Alzheimer’s patients show a dramatic reduction in glucose metabolic capacity. This isn’t just a minor inefficiency; it’s a fundamental energy crisis that precedes and likely drives cognitive decline. Brain imaging studies consistently show that glucose uptake in the hippocampus and cortex (regions crucial for memory) drops in Alzheimer’s patients long before symptoms appear, suggesting that metabolic collapse is an early trigger rather than a late consequence. The mechanism involves a vicious cycle. Abnormal beta-amyloid and tau proteins increase IDO1 enzyme activity in the brain.

This sounds technical, but the consequence is profound: IDO1 activity prevents astrocytes from producing lactate, a critical fuel source that neurons depend on. Neurons in Alzheimer’s brains essentially lose both their primary fuel (glucose uptake declines) and their backup fuel (astrocyte-supplied lactate drops), leaving them starved of energy. Some neurons compensate by burning ketones instead of glucose, which is one reason ketone-producing diets are being investigated in Alzheimer’s research. However, this metabolic flexibility has limits—neurons cannot survive on ketones alone, and the underlying energy deficit must be addressed directly. This is why boosting cellular energy in Alzheimer’s disease requires multiple approaches: restoring glucose uptake through insulin signaling therapies, supporting mitochondrial function to use available glucose more efficiently, and providing alternative energy substrates when glucose fails. Single-drug approaches targeting only one of these pathways have consistently underperformed in clinical trials, suggesting that Alzheimer’s energy crisis is complex and multifactorial.

Glucose Metabolism Collapse in Alzheimer's Disease

Therapeutic Strategies That Target the Energy Crisis

Researchers have identified several complementary strategies for restoring brain energy in neurodegenerative disease. The first category involves mitochondrial biogenesis—encouraging the brain to build new, healthy mitochondria to replace damaged ones. Exercise, caloric restriction, and compounds like resveratrol activate pathways that promote mitochondrial biogenesis, which is one reason why physical and cognitive activity appear protective against neurodegeneration. However, lifestyle interventions alone rarely reverse established disease; they work best as prevention in cognitively normal older adults. The second category involves mitochondrial dynamics—the ability of cells to fuse damaged mitochondria with healthy ones and selectively destroy irreparably damaged mitochondria through a process called mitophagy. Urolithin A is a natural compound that enhances mitophagy, essentially improving the brain’s ability to take out damaged mitochondria trash.

A Phase 2 clinical trial is currently testing urolithin A specifically for Alzheimer’s disease, marking the first time a mitophagy-enhancing compound has reached human testing for neurodegeneration. The advantage of targeting mitophagy is that it addresses quality control directly—rather than trying to force damaged mitochondria to work better, it removes them and allows healthy mitochondria to take over. The third category combines NAD precursors with PARP1 inhibitors, as mentioned earlier. This combination targets two levels of the energy problem: it boosts NAD availability (the fuel currency) while simultaneously preventing NAD depletion (slowing the leak in the bucket). In laboratory models, this combination improved mitochondrial ATP production, reduced oxidative stress, and lowered neuroinflammation. The tradeoff is that PARP1 inhibitors were originally developed for cancer treatment and carry potential side effects, so clinical testing will need to determine whether these compounds are safe and effective in neurodegenerative disease at doses that actually help the brain.

What Energy Restoration Cannot Yet Fix

While the evidence for targeting cellular energy is genuinely promising, it’s crucial to understand the limitations. Boosting energy production in neurons with advanced neurodegeneration may not reverse severe cognitive decline if the damaged neurons have already died. In Alzheimer’s disease, significant neuronal loss occurs, particularly in the hippocampus and cortex. Restoring energy to neurons that no longer exist obviously cannot restore their function. This is why researchers increasingly emphasize that energy restoration strategies must be used as prevention or in the early stages of disease, not as a last-resort treatment for severe dementia. There is also the question of specificity: can energy-boosting therapies be targeted to the brain preferentially, or will systemic treatment affect the entire body? NAD precursors given orally reach multiple tissues, not just the brain, which creates both opportunities and risks. Enhanced mitochondrial function in other organs might improve overall health (a positive side effect), but could also cause unintended consequences in tissues that depend on different metabolic patterns.

Additionally, Parkinson’s disease involves dopamine neuron death in the substantia nigra, while Alzheimer’s affects broader cortical regions. A therapy that boosts energy metabolism generally might help some patients with certain disease stages while failing to help others, which is why future clinical trials will need careful patient stratification. The timeline of treatment also matters considerably. A 65-year-old with normal cognition might benefit from NAD precursor supplementation as a preventive approach for the next 20 years. A 75-year-old with mild cognitive impairment might get some benefit. An 85-year-old with advanced Alzheimer’s disease probably will not see cognitive recovery from energy restoration alone, though such treatment might slow further decline. The problem is that we currently lack biomarkers to determine which patients have preserved enough neural tissue to benefit, which is why ongoing clinical trials are so critical.

The OTULIN Breakthrough and Immune-Driven Neurodegeneration

A remarkable discovery in early 2026 revealed a previously unknown connection between immune regulation and tau accumulation. Researchers identified OTULIN, an immune-regulating enzyme, as a master trigger of tau buildup in the brain. This finding is significant because tau—one of the hallmark proteins in Alzheimer’s disease—has been the target of numerous failed therapies. When OTULIN was disabled in animal models, tau disappeared from neurons and brain cells remained healthy. This suggests that the immune system is actively driving tau accumulation, not passively responding to it.

This discovery has important implications for energy-based therapies. If immune activation is driving tau accumulation, and tau reduces astrocyte energy production (as discussed earlier), then targeting OTULIN or immune pathways might complement energy restoration therapies. A combined approach using OTULIN inhibition plus NAD+ supplementation could theoretically address both the immune trigger and the resulting energy crisis. However, OTULIN is newly identified, and developing drugs to target it will take years. The significance of this finding is that it opens a new therapeutic avenue and suggests that future Alzheimer’s treatments might combine energy restoration, immune modulation, and tau-specific therapies rather than relying on any single approach.

What’s Next—Clinical Translation and Real-World Applications

The journey from laboratory discoveries to patient treatment typically takes 10-15 years. NAD+ supplementation and urolithin A represent the closest to human testing among the energy-targeting therapies discussed here. The Phase 2 trial for urolithin A in Alzheimer’s disease is particularly important because it will reveal whether improving mitochondrial quality through mitophagy enhancement actually translates to cognitive benefits in human patients. If successful, it could open the door for similar approaches in Parkinson’s and Huntington’s disease.

Looking forward, the most promising near-term developments involve combination therapies. Rather than seeking a single “silver bullet” drug, researchers are increasingly designing treatments that simultaneously address mitochondrial dysfunction, restore NAD metabolism, optimize glucose and lipid metabolism, and correct mitochondrial dynamics. The 2025 research showing that NAD+ supplements combined with lifestyle factors improved cognitive outcomes suggests that even while we await perfect drugs, there may be actionable steps available now. For patients and families concerned about brain health, the practical takeaway is that keeping mitochondria healthy through exercise, cognitive engagement, metabolic health, and avoiding toxins remains the most evidence-supported strategy—and now, emerging therapies may soon offer additional tools to slow the energy crisis that drives neurodegeneration.

Conclusion

The evidence increasingly suggests that boosting cellular energy can slow multiple aging-related brain disorders because mitochondrial dysfunction is not a quirk of individual diseases but a shared mechanism underlying Alzheimer’s, Parkinson’s, and Huntington’s disease. As NAD levels decline with age and mitochondrial quality control fails, the brain’s power supply collapses, allowing toxic proteins to accumulate and neurons to degenerate. Recent breakthroughs—from NAD+ supplementation reversing tau-related RNA splicing errors to OTULIN emerging as a master immune regulator of tau accumulation—have transformed this from a theoretical concern into an actionable therapeutic focus.

For patients and families facing neurodegeneration, the immediate lesson is that brain health protection requires energy protection. Supporting mitochondrial function through exercise, metabolic health, cognitive engagement, and avoiding neurotoxins remains the foundation. Clinical trials now underway for urolithin A, NAD precursor combinations, and future OTULIN-targeting therapies will determine whether we can intervene pharmacologically in the energy crisis itself. The convergence of multiple therapeutic approaches—restoring NAD metabolism, enhancing mitochondrial quality control, optimizing glucose utilization, and addressing immune-driven protein accumulation—offers realistic hope that future treatments could slow or prevent the cognitive decline that characterizes these devastating diseases.